BARCELONA, Spain—New guidelines for the diagnosis and treatment of pulmonary hypertension (PH), released at the recent European Society of Cardiology (ESC) Congress 2022, include a new hemodynamic ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

Earlier detection of pulmonary hypertension in the community and expedited referral of high-risk or complex patients are recommended in the European Society of Cardiology (ESC) and European ...

Please provide your email address to receive an email when new articles are posted on . There is generally high awareness surrounding the 2022 guidelines for pulmonary hypertension, although some gaps ...

Pulmonary arterial hypertension (PAH) is a severe disease with poor prognosis and shortened life expectancy. Treatment has traditionally involved the sequential use of endothelin receptor agonists, ...

HONOLULU -- Are the updated European guidelines on pulmonary arterial hypertension (PAH) applicable to American practice? The European Society of Cardiology and European Respiratory Society guidelines ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello. I'm Dr. Vallerie McLaughlin from the University of Michigan. And welcome to this edition of Medscape InDiscussion series on ...

Lungs Heart New 2022 ESC/ERS guidelines for PH diagnosis and treatment include an algorithm for earlier detection and expedited referral for high-risk patients. New clinical guidelines for the ...

To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one ...

New European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for diagnosis and treatment of pulmonary hypertension have lowered the cutoff for defining pulmonary hypertension ...

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...